Liraglutide: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •1 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (5 countries listed)
Risk Assessment
In rodent studies, liraglutide caused dose-dependent thyroid C-cell tumors including medullary thyroid carcinoma (MTC). Contraindicated in patients with personal or family history of MTC or MEN2 syndrome.
⚠️Important Warnings
- •BLACK BOX WARNING: Thyroid C-cell tumors -- In rodents, liraglutide causes thyroid C-cell tumors. It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Liraglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- •Do not use liraglutide with other GLP-1 receptor agonists. Do not use Saxenda with Victoza or any other liraglutide-containing product.
- •Discontinue promptly if pancreatitis is suspected. Do not restart liraglutide if pancreatitis is confirmed.
- •May delay gastric emptying, which could impact absorption of orally administered medications.
- •Pregnancy: Discontinue liraglutide immediately if pregnancy is detected. Based on animal data, may cause fetal harm.
- •Acute kidney injury has been reported, typically in the setting of dehydration from gastrointestinal adverse events.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Prescription | FDA-approved as Victoza (T2D, January 2010) and Saxenda (weight management, December 2014). Saxenda expanded to adolescents 12-17 in December 2020. Generic liraglutide approved in 2025 (Teva, Meitheal). Prescription only; not a controlled substance. |
| United Kingdom | Prescription | Approved by MHRA as Victoza for T2D and Saxenda for weight management. Available via NHS for eligible patients through specialist weight management services. |
| Canada | Prescription | Approved by Health Canada as Victoza (T2D) and Saxenda (weight management). Available by prescription. |
| European Union | Prescription | Approved by EMA as Victoza (T2D, 2009) and Saxenda (weight management, 2015). Available by prescription across EU member states. |
| Australia | Prescription | Approved by TGA as Victoza for T2D. Listed on PBS for eligible patients. Saxenda approved for weight management. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 200+ community reports
View community protocolsCritical Safety Information#
Liraglutide (Victoza/Saxenda) is an FDA-approved prescription medication with well-characterized risks identified through extensive clinical programs (LEAD, LEADER, SCALE) enrolling over 15,000 participants and growing post-marketing surveillance since 2010. This page provides a comprehensive overview of known risks, the boxed warning, regulatory status, and population-specific warnings.
Boxed Warning: Thyroid C-Cell Tumors#
Liraglutide carries a boxed warning regarding the risk of thyroid C-cell tumors, shared with all GLP-1 receptor agonist class medications.
Preclinical Evidence#
In rodent carcinogenicity studies, liraglutide caused statistically significant, dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), at exposures exceeding clinically relevant doses. This effect is consistent across the GLP-1 agonist class and is mediated by sustained GLP-1 receptor activation on rodent thyroid C-cells.
Relevance to Humans#
Human thyroid C-cells have substantially lower GLP-1 receptor expression compared to rodents. Epidemiologic data from over 15 years of GLP-1 agonist market experience (liraglutide has the longest track record since 2010, with exenatide since 2005) have not demonstrated an increased incidence of MTC in humans.
Clinical Implications#
Liraglutide is contraindicated in patients with a personal or family history of MTC or MEN2. Patients should be counseled on thyroid tumor symptoms. Routine calcitonin monitoring is not recommended.
Pancreatitis Risk#
Acute pancreatitis has been reported with liraglutide. In the LEADER trial (9,340 patients, median 3.8 years), acute pancreatitis rates were similar between liraglutide (0.4%) and placebo (0.5%). Nonetheless, patients should be monitored and liraglutide discontinued if pancreatitis is suspected.
Gallbladder Disease#
Cholelithiasis and cholecystitis are reported at higher rates with liraglutide than placebo, particularly in weight management trials. In SCALE trials, cholelithiasis was reported in approximately 2.5% of liraglutide patients versus 0.8% with placebo. Rapid weight loss from any cause increases gallstone risk.
Acute Kidney Injury#
AKI has been reported with liraglutide, typically secondary to dehydration from GI adverse events. Patients with pre-existing renal impairment are at higher risk. Adequate hydration should be maintained during nausea/vomiting episodes.
Suicidal Ideation#
Post-marketing surveillance has identified reports of suicidal ideation with GLP-1 agonists including liraglutide. The FDA concluded in 2025 that available evidence does not establish causation, but monitoring continues. Patients with psychiatric history should be monitored for mood changes.
Regulatory and Legal Status#
Liraglutide is a prescription medication in all jurisdictions where approved. It is not a controlled substance. In 2025, generic versions became available in the United States, marking a significant access milestone.
| Jurisdiction | T2D (Victoza) | Weight Management (Saxenda) | Generic Available |
|---|---|---|---|
| United States (FDA) | Jan 2010 | Dec 2014 | Yes (2025) |
| European Union (EMA) | Jul 2009 | Mar 2015 | Varies by country |
| United Kingdom (MHRA) | Approved | Approved | Available |
| Canada (Health Canada) | Approved | Approved | Under review |
| Australia (TGA) | Approved | Approved | Under review |
At-Risk Populations#
Patients with MTC or MEN2 History#
Absolute contraindication due to the thyroid C-cell tumor boxed warning.
Pregnant and Breastfeeding Women#
Liraglutide should not be used during pregnancy. Animal studies showed adverse developmental effects. Discontinue immediately if pregnancy is detected. It is unknown whether liraglutide is excreted in breast milk.
Adolescents#
Saxenda is approved for adolescents aged 12-17 with obesity. GI adverse events are more common in adolescents (65%) compared to adults. Weight regain may occur after treatment discontinuation.
Patients with Gallbladder History#
Increased risk of cholelithiasis and cholecystitis during weight loss therapy. Monitor for signs and symptoms.
Risk Mitigation#
For Prescribers#
- Screen for MTC/MEN2 history before prescribing
- Assess history of pancreatitis and gallbladder disease
- Reduce insulin or sulfonylurea doses when adding liraglutide
- Counsel on GI management and hydration
- Assess weight loss response at 16 weeks (Saxenda stopping rule)
- Screen for psychiatric history
For Patients#
- Follow dose escalation schedule to minimize GI side effects
- Report persistent severe abdominal pain immediately
- Report neck lumps, difficulty swallowing, or persistent hoarseness
- Maintain adequate hydration, especially during nausea or vomiting
- Inform healthcare providers about liraglutide before any surgery
- Use effective contraception; discontinue immediately if pregnant
Related Reading#
Frequently Asked Questions About Liraglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.